Navigation Links
Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
Date:12/7/2008

TOKYO and EDISON, N.J., Dec. 7 /PRNewswire-FirstCall/ -- Daiichi Sankyo Company, Limited (TSE: 4568), announced today that it has initiated its pivotal Phase III trial for DU-176b, an investigational oral Factor Xa inhibitor, in patients with atrial fibrillation. DU-176b is being developed solely by Daiichi Sankyo.

The Phase III global study, Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation (ENGAGE-AF TIMI 48), will compare DU-176b with warfarin in preventing stroke and systemic embolic events (SEE) in patients with atrial fibrillation. The primary safety assessment will be the incidence of bleeding.

Results from a recently presented Phase II safety study showed that the incidence of major and clinically relevant non-major bleeding events reported in the once-daily DU-176b treatment groups (30 mg or 60 mg) was similar to that in the warfarin-treated patient group. The incidence of major and clinically relevant non-major bleeding events was significantly higher in the twice-daily DU-176b treatment groups (30 mg or 60 mg), compared to the warfarin group. The Phase III study will therefore randomize approximately 16,500 patients to one of three treatment groups: 30 mg DU-176b once daily, 60 mg DU-176b once daily, or warfarin. Those randomized to warfarin will be dosed once daily with dose adjustments to maintain International Normalized Ratio (INR) between 2.0 and 3.0.

This is an event-driven, Phase III, multinational, randomized, double-blind study with sites in North and South America, Africa, Asia, Europe, Australia and New Zealand. The expected median treatment duration of the study is 24 months; Daiichi Sankyo expects the study to conclude in the first half of 2012.

"There is a need for a safe and effective option for the prevention of clotting or stroke in patients with atrial fibrillation other than the current standard of care, warfarin, which
'/>"/>

SOURCE Daiichi Sankyo Company, Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
2. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
3. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
4. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
5. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
6. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
7. Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease
8. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
9. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
10. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
11. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... DALLAS , September 22, 2014 ... report "Cell Line Development Market by Product (Equipment, Media ... (Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, ... to 2019", published by MarketsandMarkets, analyzes and studies ... Browse 114 market data tables ...
(Date:9/22/2014)... 2014 CytRx Corporation (Nasdaq: CYTR ... oncology, today announced that study designs and progress from ... a pivotal global Phase 3 clinical trial in relapsed/refractory ... clinical trial in small cell lung cancer, will be ... 2014 Congress being held September 26-30, in ...
(Date:9/19/2014)... Sept. 19, 2014 Harwood Feffer LLP ( ... of directors of PDL BioPharma, Inc. ("PDL" or the ... board has breached its fiduciary duties to shareholders or ... 16, 2014, the Company disclosed: "On September 11, 2014, ... firm, Ernst & Young LLP ("EY"), that it was ...
Breaking Medicine Technology:Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 2CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 5CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 6Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2
... Feb. 23, 2011 Plexus Biomedical Inc. has been ... and Drug Administration to market the first device clinically ... Hemorrhoids associated with vaginal delivery are a frequent complication ... women in the U.S. every year. The ...
... Inc. (Nasdaq: MAPP ) today announced that the ... Citi,s 2011 Global Healthcare Conference , Wednesday, March 2, at ... , Thursday, March 3, at 10:00 a.m. ET in ... March 9, at 10:15 a.m. ET in BostonBarclays Capital 2011 ...
Cached Medicine Technology:Plexus Biomedical Inc. Gains FDA Approval of the First Medical Device to Help Prevent External Hemorrhoids During Vaginal Childbirth 2
(Date:9/22/2014)... 2014 Don Allred Insurance is pleased to ... Burlington, NC. The satellite office, located in the Holly Hill ... 15, 2014, and offer all of the same professional services ... Allred Insurance spokesperson Scott Allred cites an expanding client base ... two of the major factors driving the decision to open ...
(Date:9/22/2014)... 22, 2014 Ethane Web Technologies, an ... to have announced affordable website redesign. The website redesign ... which are unsatisfied with their present websites and want ... to pay a big amount for this job. ... advanced tool, techniques, and experienced manpower so that it ...
(Date:9/22/2014)... Colorado's grand experiment with legal recreational marijuana for adults ... revenue for the state. , According to the ... was sold in Colorado dispensaries during the first five ... , But the success of these retail shops has ... the thousands of consumers now seeking out cannabis dispensaries ...
(Date:9/22/2014)... Available research evidence supports the use of deep ... who don,t respond to other treatments, concludes a review ... , official journal of the Congress of Neurological ... Lippincott Williams & Wilkins , a part of ... specific bilateral DBS techniques are recommended for treatment of ...
(Date:9/22/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... GLOBAL MARKETS, the global market for autoimmune disease ... billion by 2019, with a five-year compound annual ... holds the highest market potential due to an ... western lifestyles. , In recent decades, autoimmune ...
Breaking Medicine News(10 mins):Health News:Allred Insurance to Open New Burlington Branch Office 2Health News:Ethane Web Technologies Announces Affordable Website Redesign Service 2Health News:Colorado Cannabis Dispensary Creates a Unique In-Store Sales System, That Leaves the Old-School Retail Approach in the Dust 2Health News:Colorado Cannabis Dispensary Creates a Unique In-Store Sales System, That Leaves the Old-School Retail Approach in the Dust 3Health News:Evidence supports deep brain stimulation for obsessive-compulsive disorder 2Health News:Evidence supports deep brain stimulation for obsessive-compulsive disorder 3Health News:Global Market for Autoimmune Disease Diagnostics to Reach Nearly $13.1 Billion in 2019; Southern Asia Holds the Highest Potential 2Health News:Global Market for Autoimmune Disease Diagnostics to Reach Nearly $13.1 Billion in 2019; Southern Asia Holds the Highest Potential 3
... known about anticancer benefits of supplements, researchers caution , SUNDAY, ... may do nothing to protect men against bladder cancer and ... , In one study examining vitamin use, researchers analyzed more ... part in prostate screenings. , More than 60 percent ...
... 30 (HealthDay News) -- A study in mice suggests that ... scientists say. , Women may begin taking part in the ... added. , "We believe that this vaccine will someday be ... same way that vaccines have prevented many childhood diseases," principal ...
... just how sticking needles into the body can ease pain. ... Nature Neuroscience, a team at the University of Rochester ... in parlaying some of the effects of acupuncture in the ... the beneficial effects of acupuncture in mice by adding a ...
... ... $125 or more by FedEx Ground service to the 48 contiguous states in acknowledgment of ... allergy products company in the country, with over 10,000 referring doctors and 22 years of ... ...
... ... , ... Insurance Services, LLC ( HCCMIS ), is now utilizing CMN for health-care provider network administration in ...   Larger worldwide network directory with 400,000+ doctors and 7,000+ ...
... shallow or unfamiliar waters, experts say , SATURDAY, May 29 ... 14 are hospitalized each year because of a diving injury, ... spinal cord injury, researchers say. , To encourage diver safety, ... near any body of water and to jump feet first ...
Cached Medicine News:Health News:Vitamins Fail to Protect Men Against Bladder Cancer 2Health News:Acupuncture's molecular effects pinned down 2Health News:National Allergy Supply Announces Free Ground Shipping For Its Customers 2Health News:HCC Medical Insurance Services Chooses CMN as Network Administrator 2Health News:Dive Safely -- Or Risk Spinal Cord Damage 2
Hoen periosteal elevators, No.3, blade width 3/4" (20 mm), total length 7 1/2" (191 mm)....
Cushing periosteal elevators, rounded edge, sharp, wide, blade width 5/8" (16 mm), length 7 1/4" (184 mm)....
Barr periosteal elevators....
Molt 9 periosteal elevators....
Medicine Products: